Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JAMA Oncol 3 524-548

[3] Siegel RL(2019)The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy Nat Rev Cancer 19 133-150

[4] Laversanne M(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028

[5] Soerjomataram I(2013)Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 134-144

[6] Jemal A(2020)Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: a randomized, double-blind Phase III Trial J Clin Oncol 38 193-202

[7] Fitzmaurice C(2017)Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing Cell 169 1342-56.e16

[8] Allen C(2019)Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications J Hematol Oncol 12 76-50.e7

[9] Barber RM(2019)CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis J Hematol Oncol 12 37-755

[10] Barregard L(2019)Specific decrease in B-cell-derived extracellular vesicles enhances post-chemotherapeutic CD8(+) T cell responses Immunity 50 738-157

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JAMA Oncol 3 524-548

[3] Siegel RL(2019)The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy Nat Rev Cancer 19 133-150

[4] Laversanne M(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028

[5] Soerjomataram I(2013)Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 134-144

[6] Jemal A(2020)Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: a randomized, double-blind Phase III Trial J Clin Oncol 38 193-202

[7] Fitzmaurice C(2017)Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing Cell 169 1342-56.e16

[8] Allen C(2019)Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications J Hematol Oncol 12 76-50.e7

[9] Barber RM(2019)CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis J Hematol Oncol 12 37-755

[10] Barregard L(2019)Specific decrease in B-cell-derived extracellular vesicles enhances post-chemotherapeutic CD8(+) T cell responses Immunity 50 738-157